The use of sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide 1 receptor agonists is indicated to reduce stroke-related readmission rates, morbidity, and mortality in people with T2D who have experienced a stroke. Newer clinicians may not be aware of the recommendations to include cardioprotective medications in the medication treatment plans of ischemic stroke patients with underlying diabetes at discharge. This presentation will address this issue in the context of best-practice recommendations.
